Videos

Jeff Fudin, PharmD, FCCP, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.

Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.

Immunogenicity is an important consideration for all biologics, not just for biosimilars, noted Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation.

Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.

Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.

University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

Martin R. Stämpfli, PhD, explains the development of COPD in his lecture at the seminar "COPD-Bridging the Gap between Science and Clinical Care."

An overview of "Get with the Guidelines " AFIB," a quality-improvement program created by the American Heart Association for health care providers.

Chris Cannon, MD, FACC, discusses 3 research papers on atrial fibrillation in this video produced by the American College of Cardiology.

Mary Lynn McPherson, PharmD, discusses the appeal of hydrocodone combination products to drug abusers.

Jeff Fudin, PharmD, FCCP, argues that there is no evidence to support categorizing hydrocodone combination products as Schedule II drugs rather than Schedule III drugs.

In the first in a series of videos on regulation of hydrocodone combination products, Mary Lynn McPherson, PharmD, discusses the dramatic increase in the use of opioids in the United States.

Interchangeability designations for biosimilars would make therapy substitutions easier for pharmacists, noted Steven Lucio of Novation, but the FDA has said they will not grant an interchangeability status to a biosimilar upon initial approval.

Fourth-generation pharmacist Joe Moose, PharmD, reflects on how pharmacy practice has changed and remained the same over the years.

Robert Granko, PharmD, MBA, explains how data analytics can help health-system pharmacies help plan their business more strategically.

Stephen F. Eckel, PharmD, MHA, discusses how the ongoing implementation of the Affordable Care Act will affect health systems generally and health-system pharmacists in particular.

Jonathan G. Marquess, PharmD, CDE, explains why going out of your way to serve diabetes patients can help grow your pharmacy's business.

Joe Moose, PharmD, discusses the importance of working with physicians and other health care providers to serve patients' needs.

Stephan Foster, PharmD, FAPha, discusses which vaccines pharmacists should be providing in addition to the seasonal influenza vaccine.

Robert Granko, PharmD, MBA, discusses the importance of building trust among those who will use data analytics and be affected by its use in health-system pharmacy.

Stephen F. Eckel, PharmD, MHA, discusses how the formation of accountable care organizations will affect health-system pharmacy and allow pharmacists to expand their range of practice.

Jonathan G. Marquess, PharmD, CDE, discusses the role that pharmacists can play in helping patients improve management of their diabetes.

Joe Moose, PharmD, discusses how his pharmacy has used technology to monitor medication adherence and to demonstrate to patients and physicians how big a problem it can be.

Steven Lucio of Novation discusses how Teva's Granix (tbo-filgrastim), which was filed through a 351(a) pathway, was approved for only 1 indication--and it was not the indication considered to be the "most definitive" for that particular product.

Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.

Manufacturing patents will play a larger role than molecule patents within the biologics development process, and these will also be a factor in terms of bringing complex products to market, argued Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.

Last year there were 11 new cancer drugs approved, and so far this year, 6 oncology medications have been approved, notes Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.

The process of adding biosimilars to formularies will be much more rigorous than what the industry is accustomed to seeing in the generic molecule space, asserted Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.

David G. Miller, RPh, discusses concerns regarding the regulatory status of compounding medications for office use by physicians or dentists.

We will see a new wave of oral antiviral hepatitis C medicines hitting the market towards the end of this year and the beginning of next year, noted Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.